Stefania Cheli

13PUBLICATIONS
21CO-AUTHORS
Major global burdens of diseaseApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Toxicology (incl. clinical toxicology)Epidemiological modellingEpidemiological methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|May 31, 2026
Fever in a palliative care setting: Clinical insights and implications from a prospective observational cohort study.

|Jan 28, 2026
Off-Label Ustekinumab and Vedolizumab in Pediatric Anti-TNFα Refractory IBD: Therapeutic Drug Monitoring Insights from a Case Series.

Stefania Cheli, Giulia Mosini, Vera Battini

|Sep 06, 2025
Olmesartan-Induced Enteropathy: Case Reports and Insights From FDA Adverse Event Reporting System (FAERS).

Ilaria Mariani, Giulia Mosini, Stefania Cheli

|May 07, 2025
NAT2 Acetylation Status Predicts Hepatotoxicity During Antituberculosis Therapy: Cumulative Risk Analysis of a Multiethnic Cohort.

Marco Schiuma, Sofia Dinegro, Vera Battini

|Dec 27, 2024
NAT2 Slow Acetylator Phenotype as a Significant Risk Factor for Hepatotoxicity Caused by Antituberculosis Drugs: Results From a Multiethnic Nested Case-Control Study.

Stefania Cheli, Alessandro Torre, Marco Schiuma

|Feb 05, 2024
Response to: "Challenges in DPYD Test Implementation in Patients Treated with Fluoropyirimidines, is DPYD Genotype Arriving on Time?" [Response to Letter].

Cristina Montrasio, Stefania Cheli, Emilio Clementi

Pageof 3

Frequent Collaborators

4 joint publications

Cristina Montrasio

3 joint publications

Sofia Dinegro

3 joint publications

Annalisa De Silvestri

3 joint publications

Emilio Clementi